Grade 3 or higher adverse events (regardless of attribution) occurred in 50.7% of the patients in the pembrolizumab group and in 31.6% of the patients in the observation group. The content is ...

Pembrolizumab (Keytruda, Merck) has picked up another indication — this time for the first-line treatment of unresectable advanced or metastatic malignant pleural mesothelioma (MPM) in ...

Pembrolizumab plus concurrent chemoradiotherapy demonstrated a higher progression-free survival rate than placebo plus ...

0001). According to Lorusso, the safety profile of pembrolizumab plus CCRT was manageable and consistent with known toxicities of the individual therapies. Grade ≥ 3 treatment-related adverse ...

The 5-year results differed little from the 3-year results (84.6% vs 76.4%) in favor of pembrolizumab. "The hazard ratio has remained stable throughout, as most of the recurrence events in triple ...

Positive opinion granted for KEYTRUDA plus chemotherapy for the first-line treatment of adult patients with primary advanced or recurrent endometrial carcinoma who are candidates for systemic therapy, ...

If your baby is crying nonstop, there is a chance they might have a diaper rash. Wetness and friction are two of the main culprits behind irritated skin outbreak. Try not to worry too much ...

Median modified PFS was 9.4 months ... rashes. Withhold or permanently discontinue KEYTRUDA depending on severity.

The incidence of grade 3 or higher treatment-related adverse events (TRAEs) in sq-NSCLC patients treated with ivonescimab was comparable to that in the pembrolizumab ... 4 new drugs are ...